Bengaluru-based BrainSightAI, a deep-tech neuroscience startup, has raised $5 million in a pre-Series A funding round. The funding was led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, and existing investors.
Through its neuroinformatics platform, VoxelBox, BrainSightAI is working to transform the diagnosis and treatment of brain disorders. Currently working with over 40 leading hospitals in India, BrainSightAI focuses on neurosurgery and radiology, particularly brain tumour cases.
The startup is now expanding its scope to include neurological and psychiatric disorders, aiming for a comprehensive approach to brain care. The new funding will support its growth across tier 1 and tier 2 cities in India. It will also boost its efforts to secure FDA certification for entry into the US and allied markets and exploratory opportunities in Africa and Southeast Asia.
Solving Brain Disorders
Additionally, BrainSightAI plans to invest in the research and development of a caregiver-focused app designed to empower families of patients with brain disorders.
The health-tech startup was founded in 2019 by CEO Laina Emmanuel and CTO Rimjhim Agrawal. Emmanuel, an ISB graduate with two decades of experience in healthcare and technology, and Agrawal, a NIMHANS PhD specialising in machine learning for neurological disorders, envisioned BrainSightAI as a platform to democratise advanced brain care.
“We are excited about the potential of connectomics to advance personalised brain care for patients and, in the long run, for everybody,” said Emmanuel.
In a previous interview with AIM, Emmanuel said that VoxelBox has already found many applications. “Today, we work with hospitals for brain tumour surgeries. Before conducting surgery, doctors want to know where the different functions of the brain are located. If doctors know, with relation to the tumour, where these networks are, they can actually do a better job of figuring out how to cut the brain,” said Emmanuel.
BrainSightAI combines AI and neuroscience to map neural connections, enabling precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders. Traditionally exclusive to institutions like Harvard and Stanford, this technology is now accessible to hospitals and patients worldwide, reinforcing BrainSightAI’s commitment to delivering impactful healthcare solutions.
At AIM’s MLDS conference last year, Agrawal presented a paper on ML-powered Neurotech in Healthcare. You may watch it here.
